600276:SSEJiangsu Hengrui Pharmaceuticals Co., Ltd. Class A Analysis

Jiangsu Hengrui Pharmaceuticals is trading at CNY 55.11, just below its 20‑day SMA of 56.32 and well under the 50‑day SMA of 58.86, indicating a short‑term bearish bias. The stock’s PE ratio of 47.5 is nearly double the industry average of 26.2, and the DCF‑derived fair value of 35.57 suggests the market is pricing in a substantial premium. Momentum indicators are mixed: MACD shows a modest bullish histogram (+0.12) but the overall trend remains bearish with a 26% 30‑day volatility and a beta close to zero, implying limited price sensitivity.
Fundamentally, the company delivers robust growth – revenue rose 12.7% YoY to CNY 30.98 bn and profit margins sit above 24%, while ROE stands at 14.3% and debt is negligible (0.14 debt‑to‑equity). Cash generation is strong, with free cash flow exceeding CNY 8.45 bn and a low payout ratio of 17%, supporting the modest 0.36% dividend yield. Recent material news highlights a promising mid‑stage trial where a Hengrui‑partnered drug achieved a 12.1% weight‑loss effect, underscoring pipeline upside. Together, the solid balance sheet and growth prospects offset the current valuation stretch, but price pressure may persist until the market re‑evaluates the upside potential.